mAbs
短名 | MAbs |
Journal Impact | 5.66 |
国际分区 | MEDICINE, RESEARCH & EXPERIMENTAL(Q1) |
期刊索引 | SCI Q2中科院 2 区 |
ISSN | 1942-0862, 1942-0870 |
h-index | 104 |
国内分区 | 医学(2区)医学医学研究与实验(3区) |
MABS 是一份致力于抗体研究和开发的艺术和科学的多学科期刊。该杂志具有很强的科学和医学重点,但也努力为更广泛的读者服务。因此,这些文章引起了科学家、临床研究人员和医生以及更广泛的 MAB 社区的兴趣,包括我们参与技术转让、法律问题、投资、战略规划和治疗监管的读者。
期刊主页投稿网址涉及主题 | 生物遗传学医学免疫学化学抗体生物化学单克隆抗体内科学抗原物理基因免疫系统计算生物学分子生物学计算机科学受体有机化学核磁共振 |
出版信息 | 出版商: Landes Bioscience,出版周期: Bimonthly,期刊类型: journal |
基本数据 | 创刊年份: 2009,原创研究文献占比: 87.21%,自引率:12.50%, Gold OA占比: 100.00% |
平均审稿周期 | 网友分享经验:较慢,6-12周 |
期刊引文格式
这些示例是对学术期刊文章的引用,以及它们应该如何出现在您的参考文献中。
并非所有期刊都按卷和期组织其已发表的文章,因此这些字段是可选的。有些电子期刊不提供页面范围,而是列出文章标识符。在这种情况下,使用文章标识符而不是页面范围是安全的。
只有1位作者的期刊
有2位作者的期刊
有3位作者的期刊
有5位以上作者的期刊
书籍引用格式
以下是创作和编辑的书籍的参考文献的示例。
学位论文引用格式
网页引用格式
这些示例是对网页的引用,以及它们应该如何出现在您的参考文献中。
专利引用格式
最新文章
Decoding the mannose receptor-mAb interaction: the importance of high-mannose N-glycans and glycan-pairing
2024-9-8
IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine release
2024-8-28
A next-generation Fab library platform directly yielding drug-like antibodies with high affinity, diversity, and developability
2024-8-27
Developability considerations for bispecific and multispecific antibodies
2024-8-27
Expanding the structural resolution of glycosylation microheterogeneity in therapeutic proteins by salt-free hydrophilic interaction liquid chromatography tandem mass spectrometry
2024-8-27
The emergence of cell-based protein arrays to test for polyspecific off-target binding of antibody therapeutics
2024-8-24
Discovery of a novel highly specific, fully human PSCA antibody and its application as an antibody-drug conjugate in prostate cancer
2024-8-8
Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows
2024-7-31
Quantifying LAGA mutated mouse IgG2a monoclonal antibody with a rapid pepsin digestion enabled immunoaffinity LC/MS/MS assay
2024-7-30
Rapid depletion of “catch-and-release” anti-ASGR1 antibody in vivo
2024-7-25
Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers
2024-7-24
Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapy
2024-7-23
Modulation of the high concentration viscosity of IgG <sub>1</sub> antibodies using clinically validated Fc mutations
2024-7-19
Illuminating a biologics development challenge: systematic characterization of CHO cell-derived hydrolases identified in monoclonal antibody formulations
2024-7-10
Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy
2024-7-4
Early determination of potential critical quality attributes of therapeutic antibodies in developability studies through surface plasmon resonance-based relative binding activity assessment
2024-7-2
The history and potential future of monoclonal antibody therapeutics development and manufacturing in four eras
2024-7-1
Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen
2024-6-20
Synthetic integrin antibodies discovered by yeast display reveal αV subunit pairing preferences with β subunits
2024-6-18
Molecular surface descriptors to predict antibody developability: sensitivity to parameters, structure models, and conformational sampling
2024-6-10
Correction
2024-6-7
Structural analysis of light chain-driven bispecific antibodies targeting CD47 and PD-L1
2024-6-7
Insight into the avidity–affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn
2024-6-7
Large-scale data mining of four billion human antibody variable regions reveals convergence between therapeutic and natural antibodies that constrains search space for biologics drug discovery
2024-6-6
Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG <sub>1</sub> antibodies
2024-6-6
Predicting the clinical subcutaneous absorption rate constant of monoclonal antibodies using only the primary sequence: a machine learning approach
2024-5-14
Correction
2024-5-12
Antibody association in solution: cluster distributions and mechanisms
2024-4-26
Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions
2024-4-26
Targeted CQA analytical control strategy for commercial antibody products: Replacing ion-exchange chromatography methods for charge heterogeneity with multi-attribute monitoring
2024-4-23
Alternative splicing for tuneable expression of protein subunits at desired ratios
2024-4-22
Can antibodies be “vegan”? A guide through the maze of today’s antibody generation methods
2024-4-18
Reducing neonatal Fc receptor binding enhances clearance and brain-to-blood ratio of TfR-delivered bispecific amyloid-β antibody
2024-4-18
Enrichment strategy and initial characterization of heterodimers enriched from a co-formulated cocktail of therapeutic antibodies against SARS-COV-2
2024-4-9
Correction
2024-3-28
Predicting deamidation and isomerization sites in therapeutic antibodies using structure-based <i>in silico</i> approaches
2024-3-28
In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies
2024-3-27
Evaluation of the impact of antibody fragments on aggregation of intact molecules via size exclusion chromatography coupled with native mass spectrometry
2024-3-27
RUBY® – a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties
2024-3-25
T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeutics
2024-3-21
Antibody-epitope conjugates deliver immunogenic T-cell epitopes more efficiently when close to cell surfaces
2024-3-18
Do antibody CDR loops change conformation upon binding?
2024-3-13
Reduction of monoclonal antibody viscosity using interpretable machine learning
2024-3-12
A pivotal decade for bispecific antibodies?
2024-3-11
A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy
2024-3-6
Improving the integrity and reproducibility of research that uses antibodies: a technical, data sharing, behavioral and policy challenge
2024-3-6
Exploring molecular determinants and pharmacokinetic properties of IgG1-scFv bispecific antibodies
2024-3-6
Proceedings of the 14th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals
2024-3-5
Biparatopic antibodies: therapeutic applications and prospects
2024-3-4
Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies
2024-3-4
帮你贴心管理全部的文献
研飞ivySCI,高效的论文管理
投稿经验分享
分享我的经验,帮你走得更远